2024-02-13T00:00:00.000+11:00
Ongoing

Ascent 07

Ascent 07
Breast cancer

A study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients with Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy. (Other title on ANZCTR)

A study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients with Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy. (Other title on ANZCTR)

Trial overview

Topic

Breast cancer

Trial registration

Number: NCT05840211

Study details

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).

Further information

Please click here for more information

Location

GenesisCare North Shore – PI: Dr Sally Baron-Hay

GenesisCare North Shore – PI: Dr Sally Baron-Hay :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.